Technical Analysis for MCRB - Seres Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.96% | |
| 20 DMA Resistance | Bearish | -2.21% | |
| Shooting Star Candlestick | Bearish | -2.21% | |
| Doji - Bearish? | Reversal | -2.21% | |
| Wide Bands | Range Expansion | -2.21% | |
| 20 DMA Resistance | Bearish | 0.71% | |
| Wide Bands | Range Expansion | 0.71% |
| Alert | Time |
|---|---|
| Possible NR7 | 3 days ago |
| 10 DMA Resistance | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Up 2% | 3 days ago |
| Up 1% | 3 days ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Seres Therapeutics, Inc. Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Development Autoimmune Disease Antibiotics Inflammatory Bowel Disease Ulcerative Colitis Ulcer Colitis Diarrhea Digestive Diseases Antimicrobial Resistance Cdi Clostridioides Difficile Clostridium Difficile Infection Clostridium Difficile
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.26 |
| 52 Week Low | 0.54 |
| Average Volume | 4,614,155 |
| 200-Day Moving Average | 1.48 |
| 50-Day Moving Average | 0.83 |
| 20-Day Moving Average | 0.98 |
| 10-Day Moving Average | 0.93 |
| Average True Range | 0.11 |
| RSI (14) | 50.50 |
| ADX | 28.61 |
| +DI | 25.87 |
| -DI | 17.73 |
| Chandelier Exit (Long, 3 ATRs) | 0.95 |
| Chandelier Exit (Short, 3 ATRs) | 1.03 |
| Upper Bollinger Bands | 1.19 |
| Lower Bollinger Band | 0.77 |
| Percent B (%b) | 0.34 |
| BandWidth | 42.15 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0139 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.96 | ||||
| Resistance 3 (R3) | 0.96 | 0.94 | 0.95 | ||
| Resistance 2 (R2) | 0.94 | 0.93 | 0.94 | 0.95 | |
| Resistance 1 (R1) | 0.93 | 0.93 | 0.94 | 0.93 | 0.95 |
| Pivot Point | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 |
| Support 1 (S1) | 0.90 | 0.90 | 0.91 | 0.90 | 0.89 |
| Support 2 (S2) | 0.89 | 0.90 | 0.89 | 0.88 | |
| Support 3 (S3) | 0.87 | 0.89 | 0.88 | ||
| Support 4 (S4) | 0.87 |
